传染病中的共刺激和共抑制受体途径
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.
作者信息
Attanasio John, Wherry E John
机构信息
Institute for Immunology and Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Institute for Immunology and Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
出版信息
Immunity. 2016 May 17;44(5):1052-68. doi: 10.1016/j.immuni.2016.04.022.
Abstract
Costimulatory and inhibitory receptors play a key role in regulating immune responses to infections. Recent translation of knowledge about inhibitory receptors such as CTLA-4 and PD-1 into the cancer clinic highlights the opportunities to manipulate these pathways to treat human disease. Studies in infectious disease have provided key insights into the specific roles of these pathways and the effects of their manipulation. Here, recent studies are discussed that have addressed how major inhibitory and costimulatory pathways play a role in regulating immune responses during acute and chronic infections. Mechanistic insights from studies of infectious disease provide opportunities to further expand our toolkit to treat cancer and chronic infections in the clinic.
摘要
共刺激和抑制性受体在调节对感染的免疫反应中起关键作用。最近，诸如CTLA-4和PD-1等抑制性受体的相关知识被转化应用于癌症临床治疗，这凸显了通过操控这些信号通路来治疗人类疾病的可能性。传染病研究为这些信号通路的具体作用及其操控效果提供了关键见解。本文将讨论近期的一些研究，这些研究探讨了主要的抑制性和共刺激信号通路在急性和慢性感染过程中如何调节免疫反应。传染病研究中的机制性见解为进一步扩充我们在临床治疗癌症和慢性感染的手段提供了机会。
相似文献
1
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.传染病中的共刺激和共抑制受体途径
Immunity. 2016 May 17;44(5):1052-68. doi: 10.1016/j.immuni.2016.04.022.
2
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.淋巴细胞激活基因-3、T细胞免疫球蛋白黏蛋白-3和T细胞免疫受体Ig和ITIM结构域：在免疫调节中具有特殊功能的共抑制受体。
Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001.
3
KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.结核治疗后，T细胞上KLRG1和PD-1的表达增加，并在卡介苗接种的成年人中识别出具有不同增殖能力的细胞。
Tuberculosis (Edinb). 2016 Mar;97:163-71. doi: 10.1016/j.tube.2015.11.008. Epub 2015 Dec 8.
4
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.B7-CD28配体-受体家族中的共抑制通路。
Immunity. 2016 May 17;44(5):955-72. doi: 10.1016/j.immuni.2016.05.002.
5
Reversing T-cell Dysfunction and Exhaustion in Cancer.逆转癌症中的T细胞功能障碍与耗竭
Clin Cancer Res. 2016 Apr 15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849.
6
Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.抑制分子调节慢性感染患者 HCV 特异性 CD4+ T 细胞的扩增和恢复。
Gastroenterology. 2011 Oct;141(4):1422-31, 1431.e1-6. doi: 10.1053/j.gastro.2011.07.004. Epub 2011 Jul 18.
7
The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections.抑制性受体在人类逆转录病毒感染发病机制中的作用。
Front Immunol. 2018 Nov 27;9:2755. doi: 10.3389/fimmu.2018.02755. eCollection 2018.
8
PD-1 and autoimmunity.程序性死亡受体1（PD-1）与自身免疫
Crit Rev Immunol. 2011;31(4):265-95. doi: 10.1615/critrevimmunol.v31.i4.10.
9
Structural immunology of costimualtory and coinhibitory molecules.共刺激和共抑制分子的结构免疫学。
Sci China Life Sci. 2010 Feb;53(2):183-9. doi: 10.1007/s11427-010-0043-2. Epub 2010 Mar 7.
10
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.通过CTLA-4和PD-1途径控制外周T细胞耐受性和自身免疫
Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x.
引用本文的文献
1
New dimensions of PD-1/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives.PD-1/PD-L1抑制剂联合疗法在癌症治疗中的新维度：当前进展与未来展望
Front Immunol. 2025 Aug 27;16:1616872. doi: 10.3389/fimmu.2025.1616872. eCollection 2025.
2
Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis.病例报告：免疫检查点抑制剂对一名患有播散性毛霉菌病的难治性淋巴瘤患者显示出双重益处。
Front Med (Lausanne). 2025 Jul 2;12:1608828. doi: 10.3389/fmed.2025.1608828. eCollection 2025.
3
Platforms for studying cell-cell recognition by immune cells.用于研究免疫细胞间细胞识别的平台。
Immunol Cell Biol. 2025 Aug;103(7):636-647. doi: 10.1111/imcb.70036. Epub 2025 May 29.
4
An immune-based predictive model for HBV clearance: validation in multicenter cohorts and mechanistic insights from in vivo studies.一种基于免疫的乙肝病毒清除预测模型：多中心队列验证及体内研究的机制洞察
Virol J. 2025 May 21;22(1):153. doi: 10.1186/s12985-025-02792-w.
5
Hepatitis B virus surface antigen drives T cell immunity through non-canonical antigen presentation in mice.乙肝病毒表面抗原通过小鼠体内非经典抗原呈递驱动T细胞免疫。
Nat Commun. 2025 May 17;16(1):4591. doi: 10.1038/s41467-025-59985-8.
6
HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B.在慢性乙型肝炎中，替诺福韦诱导的乙肝病毒血症或乙肝表面抗原滴度下降并未增强乙肝病毒特异性T细胞功能。
Hepatol Commun. 2025 May 16;9(6). doi: 10.1097/HC9.0000000000000694. eCollection 2025 Jun 1.
7
Genomic analysis of progenitors in viral infection implicates glucocorticoids as suppressors of plasmacytoid dendritic cell generation.病毒感染中祖细胞的基因组分析表明，糖皮质激素是浆细胞样树突状细胞生成的抑制因子。
Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2410092122. doi: 10.1073/pnas.2410092122. Epub 2025 Apr 28.
8
Streptococcus lutetiensis inhibits CD8 IL17A TRM cells and leads to gastric cancer progression and poor prognosis.卢特链球菌抑制CD8 IL17A组织驻留记忆细胞，导致胃癌进展和预后不良。
NPJ Precis Oncol. 2025 Feb 9;9(1):43. doi: 10.1038/s41698-025-00810-2.
9
Metabolic deficiencies underlie reduced plasmacytoid dendritic cell IFN-I production following viral infection.代谢缺陷是病毒感染后浆细胞样树突状细胞I型干扰素产生减少的基础。
Nat Commun. 2025 Feb 7;16(1):1460. doi: 10.1038/s41467-025-56603-5.
10
Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy.利用AlphaFold2设计具有特定特性的人源化CD40激动剂抗体并开发用于癌症免疫治疗的抗PD-L1/CD40双特异性抗体。
Transl Oncol. 2025 Feb;52:102247. doi: 10.1016/j.tranon.2024.102247. Epub 2024 Dec 18.
本文引用的文献
1
Progress and prospects for blood-stage malaria vaccines.血液期疟疾疫苗的进展与前景
Expert Rev Vaccines. 2016 Jun;15(6):765-81. doi: 10.1586/14760584.2016.1141680. Epub 2016 Feb 3.
2
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.TIGIT标记耗竭的T细胞，与疾病进展相关，并作为HIV和SIV感染中免疫恢复的靶点。
PLoS Pathog. 2016 Jan 7;12(1):e1005349. doi: 10.1371/journal.ppat.1005349. eCollection 2016 Jan.
3
Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.接受直接抗病毒药物治疗的慢性丙型肝炎病毒感染患者的记忆再分化及淋巴细胞活化降低
J Viral Hepat. 2015 Dec;22(12):983-91. doi: 10.1111/jvh.12465. Epub 2015 Oct 7.
4
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.Fcγ 受体调节靶向 PD-1/PD-L1 轴的抗体的抗肿瘤活性。
Cancer Cell. 2015 Sep 14;28(3):285-95. doi: 10.1016/j.ccell.2015.08.004.
5
Immune Memory and Exhaustion: Clinically Relevant Lessons from the LCMV Model.免疫记忆与耗竭：来自淋巴细胞脉络丛脑膜炎病毒（LCMV）模型的临床相关经验教训。
Adv Exp Med Biol. 2015;850:137-52. doi: 10.1007/978-3-319-15774-0_10.
6
PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity.PD-1共抑制与OX40共刺激相互作用调节辅助性T细胞分化及抗疟体液免疫
Cell Host Microbe. 2015 May 13;17(5):628-41. doi: 10.1016/j.chom.2015.03.007. Epub 2015 Apr 16.
7
FcγRIIB prevents inflammatory type I IFN production from plasmacytoid dendritic cells during a viral memory response.FcγRIIB在病毒记忆反应期间可阻止浆细胞样树突状细胞产生炎性I型干扰素。
J Immunol. 2015 May 1;194(9):4240-50. doi: 10.4049/jimmunol.1401296. Epub 2015 Mar 27.
8
Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.通过糖皮质激素诱导的肿瘤坏死因子受体（GITR）介导的共刺激增强CD8 T细胞反应可解决慢性病毒感染。
PLoS Pathog. 2015 Mar 4;11(3):e1004675. doi: 10.1371/journal.ppat.1004675. eCollection 2015 Mar.
9
Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.持续性病毒感染期间Fcγ受体介导的抗体效应功能的抑制
Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10.
10
Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.在持续性病毒感染期间，由Fcγ受体介导的抗体效应功能会受到损害。
Immunity. 2015 Feb 17;42(2):367-378. doi: 10.1016/j.immuni.2015.01.009. Epub 2015 Feb 10.
Zotero 插件